Citius Pharmaceuticals Inc (CTXR NASDAQ) stock market data APIs
$1.144
0.04(3.5%)
as of September 15, 2025
Try our APIs with
free plan!
Citius Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Prev. Close
1.144
Open
1.1868
High
1.1859
Low
1.1289
52 wk Range
0.65-15.25
Market Cap
19 394 K
Shares Outstanding
17 012 K
EPS
-0.8
Beta
1.347
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Citius Pharmaceuticals Inc data using free add-ons & libraries
Get Citius Pharmaceuticals Inc Fundamental Data
Citius Pharmaceuticals Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -41 137 704
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: 0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Citius Pharmaceuticals Inc News
New
Citius Oncology deploys AI platform to support LYMPHIR launch
NEW JERSEY - Citius Oncology, Inc. (NASDAQ:CTOR) has implemented an artificial intelligence platform to enhance its commercial operations ahead of the anticipated launch of LYMPHIR, a treatment for cu...
Citius Oncology announces pricing of $9 million public offering
* Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]), on Wednesday announced the pricing of its "reasonable best-efforts" pub...
Cencora distribution deal boosts Citius shares
[Gratitude Concept With Heart Symbol] Eoneren * Citius Pharmaceuticals (NASDAQ:CTXR [https://seekingalpha.com/symbol/CTXR]) traded higher in the premarket on Tuesday after the company announced tha...
Citius Pharmaceuticals Prepares for Q2 2025 Commercial Launch of FDA-Approved Cancer Drug LYMPHIR
Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the best hot stocks to buy according to Wall Street analysts. In the middle of June, Citius Oncology, which is an oncology-focused subsidiary of Cit...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
